Lincoln Pharmaceuticals Ltd

  • BSE Code : 531633
  • NSE Symbol : LINCOLN
  • ISIN : INE405C01035
  • Industry :PHARMACEUTICALS - INDIAN - FORMULATIONS

up-arrow 710.35 31.45(4.63%)

Open Price ()

691.85

Prev. Close ()

678.90

Volume (No’s)

226,332

Market Cap ()

1,359.82

Low Price ()

690.00

High Price ()

723.80

 

Board Meetings

Start Date End Date Purpose
18-May-2026 28-May-2026 Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31, 2026.
04-Feb-2026 12-Feb-2026 Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve unaudited Financial Results (Standalone And Consolidated) Of The Company For The Third Quarter And Nine Months Ended 31st December, 2025 And Other Business if any. Outcome of the meeting held today. (As per BSE announcement dated on : 12.02.2026)
05-Nov-2025 13-Nov-2025 Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter and Half Year ended 30.09.2025. UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025 (As per BSE Announcement dated on: 13.11.2025)
28-Jul-2025 07-Aug-2025 Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2025. UN-AUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED ON 30-JUNE-2025 (As per BSE Announcement Dated on 07/08/2025)
15-May-2025 22-May-2025 Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2025 inter alia to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31 2025. Recommended a Final Dividend of Rs. 1.80/- (i.e 18%) per equity shares of face value 10/- each for the Financial year Ended 31st March, 2025 subject to approval of the members at the ensuing A.G.M of the Company. (As Per BSE Announcement dated on 22.05.2025)

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew